Wide Ranks

BCRX

BioCryst Pharmaceuticals, Inc.

7.50

Top Statistics
Market Cap 1 B Forward PE -193.65 Revenue Growth 35.00 %
Current Ratio 2.78 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -30.01 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -64.67 Enterprise / Revenue 5.01 Price To Sales Trailing12 Months 3.77
Profitability
Profit Margins -30.01 % Operating Margins 6.57 %
Balance Sheet
Total Cash 330 M Total Cash Per Share 1.59 Total Debt 842 M
Total Debt To Equity Current Ratio 2.78 Book Value Per Share -2.26
All Measures
Short Ratio 800.00 % Message Board Id finmb_25594 Fax 919 859 1314
Shares Short Prior Month 22 M City Durham Uuid 96bb866f-1671-37bb-8fb4-22c003011687
Previous Close 7.49 First Trade Date Epoch Utc 762 M Book Value -2.26
Beta 1.89 Total Debt 842 M Volume 1 M
Fifty Two Week Low 4.03 Total Cash Per Share 1.59 Total Revenue 412 M
Shares Short Previous Month Date 1 B Target Median Price 11.00 Max Age 86400
Recommendation Mean 1.73 Sand P52 Week Change 0.3133 Operating Margins 6.57 %
Target Mean Price 14.64 Net Income To Common -123817000 Short Percent Of Float 0.0900
Implied Shares Outstanding 207 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 330 M
Next Fiscal Year End 1 B Revenue Per Share 2.01 Held Percent Insiders 0.0115
Ebitda Margins -7.74 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 7.49 Target Low Price 8.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 7.62 Open 7.50
Free Cashflow 15 M State NC Dividend Yield 0.00 %
Return On Assets -0.0425 Time Zone Short Name EST Trailing Eps -0.6100
Day Low 7.42 Address1 4505 Emperor Boulevard Shares Outstanding 207 M
Price Hint 2 Target High Price 30.00 Website https://www.biocryst.com
52 Week Change 0.2755 Average Volume 1 M Forward Eps -0.0400
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 262.10 %
Is_sp_500 False Regular Market Day High 7.63 Profit Margins -30.01 %
Fifty Two Week High 8.88 Day High 7.63 Shares Short 18 M
Regular Market Open 7.50 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 5.01 Revenue Growth 35.00 % Shares Percent Shares Out 0.0893
Operating Cashflow -55725000 Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 27703
Quote Type EQUITY Industry Biotechnology Long Name BioCryst Pharmaceuticals, Inc.
Regular Market Day Low 7.42 Held Percent Institutions 0.8599 Current Price 7.50
Address2 Suite 200 Enterprise To Ebitda -64.67 Financial Currency USD
Current Ratio 2.78 Gross Margins 52.14 % Industry Disp Biotechnology
Number Of Analyst Opinions 11 Country United States Float Shares 192 M
Two Hundred Day Average 6.60 Ir Website http://investor.shareholder.com/biocryst/index.cfm Enterprise Value 2 B
Price To Sales Trailing12 Months 3.77 Forward PE -193.65 Regular Market Volume 1 M
Ebitda -31941000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases.

The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases.

The company has collaborations and in-license relationships with the Torii Pharmaceutical Co.

, Ltd.

; Seqirus UK Limited; Shionogi & Co.

, Ltd.

; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.

S.

Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.

BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.